These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

90 related articles for article (PubMed ID: 8042620)

  • 1. Subcutaneous factor IX administration to patients with hemophilia B.
    Berrettini M; Iorio P; Nenci GG; Arcieri P; Mariani G
    Am J Hematol; 1994 Sep; 47(1):61-2. PubMed ID: 8042620
    [No Abstract]   [Full Text] [Related]  

  • 2. Preclinical evaluation of a next-generation, subcutaneously administered, coagulation factor IX variant, dalcinonacog alfa.
    Nichols TC; Levy H; Merricks EP; Raymer RA; Lee ML
    PLoS One; 2020; 15(10):e0240896. PubMed ID: 33112889
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics of recombinant factor IX after intravenous and subcutaneous administration in dogs and cynomolgus monkeys.
    McCarthy K; Stewart P; Sigman J; Read M; Keith JC; Brinkhous KM; Nichols TC; Schaub RG
    Thromb Haemost; 2002 May; 87(5):824-30. PubMed ID: 12038784
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Glycoengineered factor IX variants with improved pharmacokinetics and subcutaneous efficacy.
    Brooks AR; Sim D; Gritzan U; Patel C; Blasko E; Feldman RI; Tang L; Ho E; Zhao XY; Apeler H; Murphy JE
    J Thromb Haemost; 2013 Sep; 11(9):1699-706. PubMed ID: 23692404
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Subcutaneous injection of factor IX for the treatment of haemophilia B.
    Gerrard AJ; Austen DE; Brownlee GG
    Br J Haematol; 1992 Aug; 81(4):610-3. PubMed ID: 1390251
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Coronary artery bypass grafting in a patient with hemophilia B: continuous recombinant factor IX infusion as per the Japanese guidelines for replacement therapy.
    Suzuki T; Kawamoto S; Kumagai K; Adachi O; Kanda K; Ishikawa M; Okitsu Y; Harigae H; Kurosawa S; Saiki Y
    Gen Thorac Cardiovasc Surg; 2016 Aug; 64(8):481-3. PubMed ID: 25523881
    [TBL] [Abstract][Full Text] [Related]  

  • 7. GlycoPEGylated factor IX: a new step forward.
    Mancuso ME
    Blood; 2014 Dec; 124(26):3836-7. PubMed ID: 25525079
    [No Abstract]   [Full Text] [Related]  

  • 8. Intratracheal administration of recombinant human factor IX (BeneFix) achieves therapeutic levels in hemophilia B dogs.
    Russell KE; Read MS; Bellinger DA; Leitermann K; Rup BJ; McCarthy KP; Keith JC; Khor SP; Schaub RG; Nichols TC
    Thromb Haemost; 2001 Mar; 85(3):445-9. PubMed ID: 11307812
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Treatment of hemophilia].
    Straub PW
    Dtsch Med Wochenschr; 1969 Sep; 94(37):1885-7. PubMed ID: 5356323
    [No Abstract]   [Full Text] [Related]  

  • 10. Prophylaxis in haemophilia B patients: unresolved issues and pharmacoeconomic implications.
    Santagostino E
    Haemophilia; 2010 Jul; 16 Suppl 6():13-7. PubMed ID: 20561353
    [No Abstract]   [Full Text] [Related]  

  • 11. Clinical experience with a Swedish factor IX concentrate.
    Nilsson IM; Ahlberg A; Björlin G
    Acta Med Scand; 1971 Oct; 190(4):257-66. PubMed ID: 5137259
    [No Abstract]   [Full Text] [Related]  

  • 12. Extravascular administration of factor IX: potential for replacement therapy of canine and human hemophilia B.
    Liles D; Landen CN; Monroe DM; Lindley CM; Read MS; Roberts HR; Brinkhous KM
    Thromb Haemost; 1997 May; 77(5):944-8. PubMed ID: 9184407
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biodegradable hydrophilic carriers for the oral delivery of hematological factor IX for hemophilia B treatment.
    Horava SD; Moy KJ; Peppas NA
    Int J Pharm; 2016 Nov; 514(1):220-228. PubMed ID: 27863665
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Studies on oral administration of concentrated factor IX preparation (author's transl)].
    Ueno M; Horikoshi I; Takahashi K; Sakuragawa N
    Yakugaku Zasshi; 1982 Jan; 102(2):202-6. PubMed ID: 7108750
    [No Abstract]   [Full Text] [Related]  

  • 15. Current management of hemophilia B.
    Roberts HR; Eberst ME
    Hematol Oncol Clin North Am; 1993 Dec; 7(6):1269-80. PubMed ID: 8294316
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Hemophilia B and aortocoronary bypass].
    Dimitrova A; Tsarianski G; Aleksandrov V; Kereshka P; Nachev G; Chirkov A
    Khirurgiia (Sofiia); 1995; 48(1):76-9. PubMed ID: 7474765
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Long-term low-dose secondary prophylaxis for severe and moderate hemophilia children with arthropathy in China: a single-center observation study].
    Wu RH; Wu XY; Zhang NN; Zhao L; Zhang JS; Zhen YZ; Peng Y
    Zhonghua Xue Ye Xue Za Zhi; 2013 Jul; 34(7):632-4. PubMed ID: 23906463
    [No Abstract]   [Full Text] [Related]  

  • 18. [Prevention of severe haemophilia B with a factor IX concentrate (author's transl)].
    Ludwig E; Lechner K
    Dtsch Med Wochenschr; 1974 Jun; 99(25):1355-61. PubMed ID: 4836072
    [No Abstract]   [Full Text] [Related]  

  • 19. Implementation of a recombinant factor IX Fc fusion protein extended-infusion desensitization protocol.
    Clough AM; Gilreath JA; McPherson JP; Link NC; Rodgers GM; Nance D
    Haemophilia; 2017 May; 23(3):e227-e230. PubMed ID: 28306218
    [No Abstract]   [Full Text] [Related]  

  • 20. In silico evaluation of limited blood sampling strategies for individualized recombinant factor IX prophylaxis in hemophilia B patients.
    Preijers T; Hazendonk HCAM; Fijnvandraat K; Leebeek FWG; Cnossen MH; Mathôt RAA
    J Thromb Haemost; 2017 Sep; 15(9):1737-1746. PubMed ID: 28688133
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.